Home › NDC Lookup › Drug shortages › Posaconazole Injection

Posaconazole Injection shortage

Posaconazole Injection is currently listed in shortage by the FDA. The FDA lists 1 affected product. This page was last refreshed from FDA data on Sep 24, 2026.

To Be Discontinued ⚠ Supply risk: High Anti-Infective 1 product 296 days First posted Dec 2, 2025 Updated Dec 2, 2025
Here’s the bottom line

Merck is stopping production of posaconazole injection (18 mg/mL), and this change may be permanent. The same medicine is still listed as available from other makers not reporting a shortage.

Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).

Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →
1
Affected NDCs
1
Reporting manufacturers
0/1
Reporting mfrs supplying
0/1
Affected strengths supplied
296
Days in shortage
28
Medicaid Rx (2025)
Source: FDA Drug Shortages Database API (openFDA). Last refreshed Sep 24, 2026 · yesterday

What’s in shortage — at a glance

These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Posaconazole Injection. Other makers that haven’t reported a problem are shown in the green card below.

Availability of affected NDCs
From the FDA shortage report
1 NDCs
To be discontinued 1
Affected strengths still supplied
Among manufacturers reporting this shortage
0/1 strengths
No supply 1
FDA-reporting manufacturers with supply
Among manufacturers reporting this shortage
0/1 makers
No supply 1
✓ Other manufacturers not reporting a shortage
Still-marketed Posaconazole Injection from companies that have not filed an FDA shortage — these are not counted in the figures above. Stock can still vary by pharmacy.
Camber Pharmaceuticals, Inc. Mylan Institutional LLC
Plus 16 alternative dosage forms of Posaconazole.
See all other options & details →
Shortage timeline
  1. Dec 2, 2025
    Currently in shortage
    1 of 1 product affected.
  2. Dec 2, 2025
    First reported to the FDA
    1 product first listed.

Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.

What exactly is on backorder — by manufacturer

Manufacturer: Merck Sharp & Dohme Corp. 📞 800-672-6372 1 NDC click to expand
Status NDC / product Strength Availability Related information Reason
To Be Discontinued Noxafil, Injection, 18 mg/1 mL (NDC 0085-4331-01) NDC 00085-4331-01 — — Discontinuation of the manufacture of the drug —

These rows are manufacturer reports to the FDA for Posaconazole Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Posaconazole Injection? options further down this page.

Why is Posaconazole Injection in shortage?

Merck Sharp & Dohme Corp. has reported to the FDA that they are permanently stopping the manufacture of their brand-name version of posaconazole injection, Noxafil, in the 18 mg/1 mL strength. That's the reason this product appears on the shortage list — it's not a temporary supply hiccup, but a permanent decision to stop making that specific product altogether.

It's worth knowing that this report only covers what Merck shared with the FDA about their own product. Merck did not provide a specific public reason for why they made this decision, just that the manufacturing of this particular product is being discontinued.

Based on the manufacturer-reported reason(s) and notes on file with the FDA for Posaconazole Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.

What should I do if I take Posaconazole Injection?

Posaconazole injection (18 mg/mL) is currently on the FDA drug-shortage list. I want to explain what this means for you clearly and calmly.

Only one strength exists on this record — the 18 mg/mL injection — and it is the strength affected. The manufacturer that filed this report, Merck Sharp & Dohme (its Noxafil injection), lists this product as to be discontinued. The reported reason is that the maker is stopping production of the drug. Because this is a discontinuation rather than a temporary delay, the supply problem for that specific product may be permanent, and no recovery date is given.

Please do not stop, skip, or change how you use this medicine on your own. Here is a sensible order of steps:

  1. Talk with your prescriber or pharmacist about next steps, since this product is being discontinued.
  2. Ask your pharmacy whether the same medicine — posaconazole 18 mg/mL — is available from another maker. Our records show it from Camber Pharmaceuticals and Mylan Institutional. Your pharmacy may be able to source one of these, though it may not be in local stock.
  3. For reference, the manufacturer's contact number is listed on this page; pharmacies usually handle those calls.

This is national, manufacturer-reported information and may not match your pharmacy's actual stock.

See “Where else can I get Posaconazole Injection?” below ↓ The same medicine from manufacturers not reporting a shortage, alternative dosage forms, and therapeutic equivalents with pricing.
If you are a patient:
  • Don’t stop or change the medication on your own — talk to your prescriber first.
  • If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
  • Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
  • Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Keep reading
Our full Posaconazole guide

Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.

Read the Posaconazole guide →

Where else can I get Posaconazole Injection?

FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Posaconazole Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.

Same medicine, other manufacturers (not reported short)

Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:

ProductStrengthForm / routeManufacturerNDC
Posaconazole POSACONAZOLE 18 mg/mL Solution · Intravenous Camber Pharmaceuticals, Inc. 31722-0370-31
Posaconazole POSACONAZOLE 18 mg/mL Solution · Intravenous Mylan Institutional LLC 67457-0665-20

Alternative dosage forms of Posaconazole

A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:

Therapeutic equivalents & pricing 9 productsclick to expand

Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.

ProductManufacturerPackageNADAC $/unitAB ratingAvailability
Noxafil 18 mg/mLNDC 00085-4331-01 Merck 1 vial — — FDA listed
Posaconazole 18 mg/mLNDC 31722-0370-31 Camber 1 vial — AP FDA listed
Posaconazole 18 mg/mLNDC 42023-0195-01 Par 1 vial — AP FDA listed
Posaconazole 18 mg/mLNDC 55150-0388-01 Eugia 1 vial — AP FDA listed
Posaconazole 18 mg/mLNDC 63323-0685-17 Fresensius 1 vial — AP FDA listed
posaconazole 18 mg/mLNDC 67457-0665-20 Mylan 1 vial — AP FDA listed
posaconazole 18 mg/mLNDC 68083-0577-01 Gland 1 vial — AP FDA listed
posaconazole 18 mg/mLNDC 68462-0904-01 GLENMARK 1 vial — AP FDA listed
posaconazole 18 mg/mLNDC 68462-0911-01 GLENMARK 1 vial — AP FDA listed

Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.

Other drugs in the same treatment class

These are different medicines — not other versions of Posaconazole Injection — that fall in the same broad treatment class (antifungal agents) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.

Identity & classification

GCN Seq No 072141
GCN 36248
HICL code 033461
Ingredient (HICL) Posaconazole
HIC1 code W
Therapeutic class — broad (HIC1) Anti-Infecting Agents
HIC2 code W3
Therapeutic class — intermediate (HIC2) Antimycotics
HIC3 code W3B
Therapeutic class — specific (HIC3) Antifungal Agents
AHFS code 08:14.08.00
AHFS class Azole Antifungals
FDB label name NOXAFIL 300 MG/16.7 ML VIAL
FDB brand name Noxafil
Legend status F — Federal legend — prescription drug or device
GPI-1411407060002020
GPI classNoxafil
Where does this data come from?
Identity codes come from First Databank (FDB) (HICL ingredient, HIC1–3 therapeutic-class hierarchy, GCN, AHFS class, legend status) and Medi-Span GPI, mapped from a representative affected NDC. Licensed reference data — for identification only.

Other anti-infective shortages

Posaconazole Injection shortage FAQs

Is Posaconazole Injection in shortage?
Yes — the FDA currently lists Posaconazole Injection in shortage (status: “To Be Discontinued”, first reported Dec 2, 2025). 1 of 1 product is affected. This is national, manufacturer-reported data, so your pharmacy may still have stock.
Which products are affected?
Noxafil, Injection, 18 mg/1 mL (NDC 0085-4331-01) (NDC 00085-4331-01). The full per-NDC list (availability, manufacturer and status) is in the table above — each NDC links to its own page.
When will Posaconazole Injection be available again?
The FDA does not publish a guaranteed restock date, and no estimated-recovery note is on file. Availability can change daily — confirm with your pharmacy.
Can I still get Posaconazole somewhere?
Other manufacturers (Camber Pharmaceuticals, Inc., Mylan Institutional LLC) still market it and have not reported a shortage. 16 alternative dosage forms of Posaconazole are also listed. See “Where else can I get Posaconazole Injection?” above — stock still varies by pharmacy.
What should I do if I take Posaconazole Injection?
Don’t stop or change it on your own. Ask your pharmacist whether they can order it from another manufacturer or a different strength/package size, and ask your prescriber about a long-term plan before your supply runs out.

Still have a question about the Posaconazole Injection shortage?

Ask a pharmacist about this shortage →
How to read the Supply-Risk rating
Low (1–2)Multiple manufacturers still supplying and most strengths or pack sizes sourceable.
Medium (3)Some constraint — fewer suppliers or a notable share of NDCs unavailable.
High (4–5)Down to a single source, most strengths or pack sizes unsourceable, or a long-running outage.
Where does this data come from?
Shortage records come from the FDA Drug Shortages Database API via openFDA (/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.
Data structure & sourcing designed and verified by Dr. Brian Staiger, PharmD.
← Back to all current drug shortages